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Edited by Frances ShannonAbstract Interleukin (IL)-8 is a CXC chemokine induced by
pro-inﬂammatory cytokines such as TNFa, IL-1b and IL-6 in
diﬀerent cell types including keratinocytes. IL-4 regulation of
TNFa-induced IL-8 expression is cell-type speciﬁc. In this study,
we show that in the keratinocyte cell line HaCaT, IL-4 decreases
TNFa-induced IL-8 mRNA expression. We then investigated the
mechanism of IL-4 eﬀect and showed that IL-4 downregulates
TNFa-induced IL-8 promoter activity in luciferase reporter as-
says. Moreover, overexpression of either the endogenous JAK
inhibitor SOCS-1 or a dominant negative form of the STAT6
transcription factor (STAT6DC) interferes with the IL-4 inhibi-
tory eﬀect on IL-8 promoter. Finally we demonstrate, using a
NF-jB-dependent promoter luciferase construct that IL-4 inter-
feres, at least in part, with NF-jB transcriptional activity. Over-
all our results suggest that IL-4 regulates TNFa-induced IL-8
expression at a transcriptional level and this mechanism involves
STAT6 and NF-jB transcription factors.
 2005 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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IL-4 is a pleiotropic cytokine produced by TH2-type lym-
phocytes and mast cells and is known to play a key role in
allergic inﬂammation. Divergent eﬀects of IL-4 were found
on hematopoietic cells and ﬁbroblasts or epithelial cells. In
the monocyte/macrophage lineage, IL-4 displays anti-inﬂam-
matory properties for example by inhibiting LPS-induced
IL1b, TNFa and IL-10 production [1]. Conversely, on ﬁbro-
blasts and epithelial cells, IL-4 either potentiates or inhibits ba-
sal levels or TNFa-induced chemokine production [2,3].
Keratinocytes are major structural components of epidermis
and participate in the initiation and/or regulation of cutaneous
inﬂammatory and immune responses as a result of their ability
to produce a variety of cytokines and chemokines. In responseAbbreviations: C/EBP, CCAAT/enhancer-binding protein; IFN, inter-
feron; IP-10, IFN-c-inducible protein 10; ITAC, IFN inducible T-cell
a-chemoattractant; JAK, janus kinase; LPS, lipopolysaccharides;
MDC, macrophage-derived chemokine; MIG, monokine induced by
IFN-c; SOCS, suppressor of cytokine signalling; STAT, signal trans-
ducer and activator of transcription; TARC, thymus and activation-
regulated chemokine
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they synthesize and release IL-6 and IL-8 [4]. On these cells,
IL-4 stimulates IL-6 production through a p38MAPK-depen-
dent stabilization of the IL-6 mRNA [5]. IL-4 also downregu-
lates TNFa-induced MDC or thymus and activation-regulated
chemokine (TARC) production but synergizes with TNFa to
release the IFN-c-inducible protein 10 (IP-10), monokine in-
duced by IFN-c (MIG) and IFN inducible T-cell a-chemoat-
tractant (ITAC) chemokines [6,7]. In keratinocytes, IL-4 and
IL-13 share a common receptor composed of a heterodimer
of the IL-4Ra and IL-13Ra1 chains. Binding of IL-4 to its
receptor leads to the activation of the janus kinase (JAK)/
STAT6 signal transduction pathway and to the MAPK Erk
and p38 cascades [5,8]. STAT6 phosphorylation by JAK tyro-
sine kinase triggers its homodimerization and its translocation
to the nucleus where it regulates gene transcription. We and
others have shown that IL-4-induced IL-13Ra2 receptor chain
and eotaxin 1 expression is mainly mediated by STAT6 [9,10].
Recently we demonstrated that suppressor of cytokine signal-
ling-1 (SOCS-1) gene expression is regulated transcriptionally
by STAT6 [11]. SOCS-1 participates in the downregulation
of the IL-4 receptor activity. Part of the mechanism involves
SOCS-1 interaction with JAK kinases, triggering their inacti-
vation and degradation [12].
IL-8 is a member of the CXC chemokine family involved in
recruitment of leukocytes to the site of inﬂammation [13]. Nor-
mally, non-induced cells secrete a very low amount of IL-8;
however, its production is rapidly induced by a wide range
of stimuli such as pro-inﬂammatory cytokines, bacterial or vir-
al products and cellular stress [14]. IL-8 synthesis is controlled
at transcriptional or post-transcriptional levels. While NF-jB,
Erk and JNK signal transduction pathways regulate IL-8 pro-
moter activity, p38 MAPK rather regulates IL-8 synthesis at
the mRNA level. The IL-8 promoter contains NF-jB binding
sites. NF-jB is sequestered in the cytoplasm through interac-
tion with the IjB inhibitory proteins. Upon stimulation, IjB
becomes phosphorylated and targetted to the proteasome
allowing NF-jB to translocate to the nucleus and bind to
DNA. Ultimately, enhanced NF-jB-induced transcriptional
activity might additionally require phosphorylation of the
NF-jB subunits as well as binding of co-activators [15].
Here we demonstrate that in the keratinocyte cell line
HaCaT, IL-4 inhibits TNFa-induced IL-8 mRNA expression.
The regulation occurs at the transcriptional level and involves
the JAK/STAT6 pathway. Furthermore, downregulation
of the IL-8 promoter activity partially occurs through inibition
of NF-jB transcriptional activity without aﬀecting its nuclear
translocation.ation of European Biochemical Societies.
Fig. 1. IL-4 inhibits TNFa-induced IL-8 mRNA expression in HaCaT
cells. HaCaT cells were cultured for 18 h with the indicated cytokine.
Total RNA was then extracted and IL-8 mRNA expression was
measured by RT-PCR (Panel A), and real-time RT-PCR (Panel B).
(A) IL-8 PCR fragments were visualized on a 2% agarose gel which
was stained with ethidium bromide (1 lg/ml). Representative data of
two independent experiments with similar results are shown. (B) IL-8
mRNA level was compared to 28S and GAPDH mRNA level used as
control and represented as fold change. The data are the mean of three
experiments ± S.D.
3954 J. Raingeaud, J. Pierre / FEBS Letters 579 (2005) 3953–39592. Materials and methods
2.1. Reagents
Recombinant human TNFa and IL-4 were added to the medium at a
ﬁnal concentration of 2 and 10 ng/ml, respectively, unless speciﬁed.
Anti-IjBa (sc-371), anti-p65/RelA (sc-109) and anti-STAT6 (sc-621)
antibodies were from Santa Cruz. Anti-Phospho-Tyr 641-STAT6
(#9361) antibody was from Cell Signaling Technology. Anti-b-tubulin
antibody (T-4026) was from Sigma–Aldrich.
2.2. Cell culture
The human keratinocyte cell line HaCaT was provided by
N. Fusenig and cultured in Dulbeccos modiﬁed Eagles medium sup-
plemented with antibiotics (50 lg/ml penicillin and 50 lg/ml strepto-
mycin), 1 mM sodium pyruvate and 10% fetal bovine serum. Human
embryonic kidney 293T cells are from ATCC and were cultured in
the same medium.
2.3. Plasmids
The plasmids encoding STAT6WT and STAT6DC have already
been described [11]. The SOCS-1 expressing vector is a generous gift
from Dr. Yoshimura [16]. The pNF-jB-luc plasmid was provided by
Dr. M. Rincon [17]. The reporter plasmids containing the IL-8 pro-
moter driving the ﬁreﬂy luciferase gene were constructed as follows.
The 1400 and 173 bp IL-8 promoter constructs were gifts from Dr.
M.A. Buendia [18]. The 2000 bp IL-8 promoter was generated by
PCR from HaCaT genomic DNA using the forward primer
TTGTGGTACCTATCCGGCCCAAGCTTTC and the reverse pri-
mer TCCTCTCGAGCTTGTGTGCTCTGCTGTCTC. The 2000 bp
fragment was then subcloned in the KpnI–XhoI sites into the pGL3 ba-
sic vector.
2.4. RT-PCR
Total RNA was extracted with Trizol (Invitrogen) as described by
the manufacturers instruction, treated with DNase I (Roche Molecu-
lar Biochemical) and quantiﬁed at OD260 nm. 2 lg of total cellular
RNA was reverse-transcribed using an oligo(dT) primer (MWG Bio-
tech, Les Ulis, France) and 1.6 unit of AMV reverse transcriptase (Pro-
mega, Madison, WI, USA) and then used as template for PCR.
Equivalent quantities of cDNA were ampliﬁed by real-time PCR using
the LightCycler-DNA Master SYBR Green I Kit, Roche Molecular
Biochemicals. The standard PCR was carried out with Taq DNA ploy-
merase from Qbiogene. The cycling conditions were 94 C for 30 s,
61 C for 1 min and 72 C for 1 min for a total of 35 cycles. Primers
ampliﬁed a 301, 109 and 113 bp fragment of IL-8, 28S and GAPDH
cDNA, respectively. The speciﬁc pairs of primers were CAT-
GACTTCCAAGCTGGCCG and TTTATGAATTCTCAGCCCTC
for IL-8, CGGGTAAACGGCGGGAGTAA and GGTAGGGA-
CAGTGGGAATCT for 28S and GTGAAGGTCGGAGTCAACG
and TGAGGTCAATGAAGGGGTC for GAPDH.
2.5. Transfection
Transfection assays were carried out using JetPEITM method
(Polyplus transfection, Illkirch, France). Transfection eﬃciency was
normalized by co-transfection of the cells with a 50 ng of pSRa-Re-
nilla luciferase expression vector. After 24 h incubation, cells were
supplemented with fresh serum-free culture medium and left unstim-
ulated or stimulated with cytokines for 24 h. Cells were lysed to pro-
ceed to a dual luciferase assay according to the manufacturers
instructions (Promega). Fireﬂy and Renilla luciferase activities were
measured on a MicroLumat Plus LB 96 V Luminometer (Bertold
Technologies, Bad Wild-bad, Germany). Results were expressed as
fold increase relative to the basal activity measured in unstimulated
transfected cells.
2.6. Western blot analysis
After stimulation with IL-4 and/or TNFa, cell were lysed in Triton
Lysis Buﬀer (20 mM Tris (pH 7.4), 10% glycerol, 1% Triton X-100,
0.137 M NaCl, 25 mM sodium b-glycerophosphate, 2 mM EDTA,
0.5 mM dithiotreitol, 1 mM sodium orthovanadate, 2 mM sodium
pyrophosphate, 10 lg/ml leupeptin, 1 mM phenylmethylsulfonyl ﬂuo-
ride). The cell extracts were centrifuged at 15000 · g (15 min, 4 C).
Proteins were fractionated by SDS–PAGE, electrophoretically trans-ferred to a Hybond-C Extra membrane (Amersham–Pharmacia
Biotech, Uppsala, Sweden) and probed with appropriate antibodies.
b-tubulin was used as internal loading control. Immunocomplexes
were detected using chemiluminescence assay (Amersham–Pharmacia
Biotech). Nuclear extracts were prepared as described previously [5].3. Results
3.1. Inhibition of TNFa-induced IL-8 mRNA expression by IL-4
In keratinocytes, as in ﬁbroblastic and hematopoietic cells,
TNFa stimulates IL-8 expression [19]. Regulation of IL-8
expression by IL-4 is cell-type speciﬁc. Whereas in monocytes
IL-4 inhibits LPS-induced IL-8 expression [20], in bronchial
epithelial cells (BEAS), IL-4 and TNFa act in synergy to pro-
duce IL-8 [21]. We ﬁrst sought to analyse by RT-PCR the eﬀect
of IL-4 on the induction of IL-8 transcript by TNFa in HaCaT
cell line. HaCaT cells were incubated with either IL-4 or TNFa
alone or both cytokines for 18h. While IL-4 alone had no eﬀect
on basal IL-8 mRNA level, we observed an inhibition by IL-4
of TNFa-induced IL-8 mRNA (Fig. 1A). To evaluate more
precisely IL-8 mRNA expression by these cytokines, we used
real time RT-PCR. As shown in Fig. 1B, IL-4 inhibits up to
60–70% IL-8 mRNA expression induced by TNFa in these
cells as compared to the cells treated with TNFa alone. Thus
in HaCaT cells, IL-4 downregulates TNFa-induced IL-8
expression.
3.2. Inhibition of TNFa-induced IL-8 promoter activation by IL-4
IL-8 regulation by TNFa occurs at the transcriptional and
post-transcriptional levels involving the IKK/NF-jB, JNK/
AP-1 and p38MAPK pathways [14]. In addition, analysis of
the IL-8 promoter region, reveals a STAT6 consensus binding
site at 1850 bp upstream the transcriptional start site. In order
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tional level and whether this consensus STAT6 binding site
was involved in the regulation, we cloned, from HaCaT geno-
mic DNA, the ﬁrst 2000 bp of the IL-8 promoter which
includes this element. This fragment was then inserted in the
promoterless pGL3-basic, a luciferase reporter plasmid. In or-
der to identify potential IL-4 regulated elements, three trun-
cated forms of the IL-8 promoter were analysed: 2000, 1400
and 173 bp (Fig. 2A). As shown on Fig. 2B, in HaCaT cells,
IL-4 inhibits TNFa-induced activation of the three truncated
forms of the IL-8 promoter, whereas the activity of the paren-
tal plasmid, pGL3-basic is not modiﬁed by IL-4 and/or TNFa
stimulation (data not shown). Moreover, there was no diﬀer-
ence in the extent of inhibition among the three 5 0 promoter
deletion constructs tested. When cells were treated with
increasing amount of IL-4, this cytokine dose-dependently
inhibited IL-8 promoter activation by TNFa (Fig. 2C). Fur-
thermore IL-13, which in these cells, shares a common receptor
and various biological activities with IL-4 has the same eﬀect
(data not shown). These data indicate that IL-4-mediated IL-8
regulation occurs at the transcriptional level and suggest thatFig. 2. IL-4 downregulates TNFa-induced IL-8 promoter activation.
(A) Schematic representation of the IL-8 promoter constructs used and
binding sites for nuclear factors. (B–C) HaCaT cells were transfected
with 0.4 lg of IL-8 promoter-luciferase plasmids for 24 h and then
stimulated with the indicated cytokine for 24 h. The data are the mean
of four experiments ± S.D. The results are expressed as fold increase in
relative light units to the level in unstimulated cells. (B) Comparison of
the activity of the diﬀerent truncated IL-8 promoter constructs. (C)
Dose response eﬀect of IL-4 on the regulation of TNFa-induced
p2000-IL-8-luciferase.the IL-4-dependent region is restricted to the ﬁrst 173 bp of
the IL-8 promoter.
3.3. SOCS-1 expression interferes with inhibition of
TNFa-induced IL-8 promoter activation by IL-4
JAK kinase phosphorylation and activation is an early and a
major event in the signalling pathways activated upon IL-4
binding to its receptor. To determine whether the JAK tyrosine
kinase pathway was involved in IL-4 mediated IL-8 promoter
inhibition, we transfected HaCaT cells with a SOCS-1 expres-
sion vector or parental vector along with the IL-8 promoter
luciferase constructs 2000 and 173 bp. The results in Fig. 3
show that SOCS-1 overexpression completely abolishes the
inhibitory eﬀect of IL-4 on TNFa-induced IL-8 promoter acti-
vation, indicating that the JAK pathway is involved in the
inhibitory eﬀect of IL-4.
3.4. IL-4 inhibition of TNFa-induced IL-8 promoter activation is
mediated by STAT6
In IL-4-stimulated keratinocytes, downstream eﬀectors of
the JAKs, include the STAT6 transcription factor. In order
to investigate whether STAT6 was involved in IL-4 regulatory
eﬀect we transfected HaCaT cells with a STAT6 truncated of
its transactivation domain (STAT6DC). Such a mutant is still
able to bind DNA and behaves as a dominant negative. As pre-
sented in Fig. 4A, expression of STAT6DC reduces inhibition byFig. 3. SOCS-1 expression suppresses IL-4-mediated downregulation
of IL-8 promoter activation. HaCaT cells were transfected with 0.4 lg
of pIL-8 promoter-luc with 0.4 lg of SOCS-1 expression vector or
parental vector for 24 h and then stimulated as indicated for 24 h. The
data are the mean of three experiments ± S.D.
Fig. 4. STAT6 pathway is involved in IL-4 mediated downregulation of IL-8 promoter activation. (A) HaCaT cells were transfected with 0.4 lg of
pIL-8 promoter-luc with 0.4 lg of parental or pSTAT6DC expression vector for 24 h and then stimulated as indicated for 24 h. Experiments were
performed at least three times. Means ± S.E.M. are presented. (B) HEK 293T cells were transfected with 0.4 lg of pIL-8 promoter-luc with 0.4 lg of
parental or pSTAT6WT expression vector for 24 h and then stimulated as indicated for 24 h. Experiments were performed four times.
Means ± S.E.M. are presented. Data were analysed using the Students t test. \P < 0.05, \\P < 0.001 compared to the TNFa stimulated cells. (C) 293T
were transfected with STAT6WT expression vector for 24 h. Then parental 293T, 293T transfected with STAT6WT and HaCaT cells were stimulated
with TNFa without or with IL-4 for 30 min and lysed in TLB. 30 lg of protein extracts was separated by SDS–PAGE and expression or
phosphorylation of STAT6 protein was assessed by Western blot.
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8 promoter from 60% to around 15%.
To further assess STAT6 contribution, we examined IL-4
inhibitory eﬀect on the TNFa-induced IL-8 promoter activa-
tion in the STAT6-deﬁcient cell line HEK 293T. As shown
in Fig. 4B, IL-4 treatment does not have any eﬀect on IL-8
promoter activation by TNFa in 293T.
To test the actual implication of STAT6 in the IL-4 down-
regulation of IL-8 promoter activity, we reintroduced by trans-
fection the wild type STAT6 cDNA in 293T cells and
co-stimulated them with IL-4 and TNFa. As presented in
Fig. 4B, STAT6WT overexpression partially restores inhibi-
tion of TNFa-induced IL-8 promoter activation by IL-4. In
control experiments, a phospho-Tyr641-STAT6 Western blotconﬁrms the integrity of the IL-4 signalling pathway in 293T
cells upon ectopic STAT6 expression (Fig. 4C). Altogether,
these data demonstrate that the inhibition by IL-4 of the acti-
vation of the IL-8 promoter induced by TNFa is mediated by
STAT6.
3.5. Inhibition of TNFa-induced IL-8 promoter activation by IL-4
involves NF-jB transcription factor
In a last set of experiments, we sought to determine whether
IL-4 interferes with NF-jB transcriptional activity. Several
studies reported an inhibitory eﬀect of IL-4 and IL-13 on
TNFa signalling pathway via downregulation of NF-jB activ-
ity [22–24]. To further examine the regulatory eﬀect of IL-4 on
the NF-jB pathway, we looked for TNFa-induced IjBa
Fig. 5. IL-4 inhibits TNFa-induced NF-jB transcriptional activity.
(A) Upper panel: HaCaT cells were treated with TNFa alone or IL-4 +
TNFa for the indicated period of time and total cells lysates were
prepared. Lower panel: HaCaT cells were treated with TNFa alone or
IL-4+TNFa for 30 min and nuclear extracts were prepared. For both
experiments, 20 lg of protein extracts were subjected to immunoblot
with an anti-IjBa (dilution 1/5000) and anti-p65 (dilution 1/1000)
antibodies. (B) HaCaT cells were transfected with 0.3 lg of pNF-jB-
luc plasmid for 24 h then stimulated with cytokines for 24 h as
indicated. Results are presented as percentage of activation as
compared to TNFa activation (100%). The data are the mean of three
experiments ± S.D.
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stimulatory experiments. As shown in Fig. 5A, in HaCaT cells,
neither IjBa degradation nor p65 translocation to the nucleus
were decreased by IL-4 treatment. Similar results were ob-
tained when cells were pretreated with IL-4 for up to 8 h. Fi-
nally, we measured NF-jB transcriptional activity in a NF-
jB-dependent promoter luciferase assay. Although IL-4 does
not prevent NF-jB from translocating to the nucleus, it inhib-
ited its ability to activate transcription (Fig. 5B). This result
supports the idea that in HaCaT cells, inhibition of TNFa-in-
duced IL-8 promoter activation by IL-4 occurs in part via
downregulation of NF-jB transcriptional activity.4. Discussion
IL-8 expression is induced by a wide range of stimuli in
keratinocytes including TNFa. In other types of epithelial cells
IL-4 either inhibits or cooperates with TNFa to release IL-8
[21,25]. In this study, we have investigated the mechanism by
which the TH2-derived cytokine IL-4 modulates IL-8 synthesis
induced by TNFa in the HaCaT cell line. Our results demon-
strate that in these cells, IL-4 inhibits TNFa-induced IL-8
production. In fact Wang et al. [20] showed that IL-4 inhibits
LPS-induced IL-8 expression in peripheral blood mononuclear
cells through IL-8 mRNA degradation. In HaCaT cells, this
regulation occurs at the transcriptional level since IL-8promoter activity is downregulated by IL-4 (Fig. 2B), although
we can not exclude an eﬀect of IL-4 on IL-8 mRNA stability.
Of note, a similar inhibition eﬀect of IL-4 has also been re-
ported on histamine-induced IL-8 expression [26]. Moreover
in these cells, depending on target gene, IL-4 and TNFa may
also cooperate to induce gene expression [10].
We conﬁrmed that IL-8 promoter inhibition resulted specif-
ically from JAK signalling pathway by overexpressing the
SOCS-1 protein, a JAK inhibitor. Besides its ability to interact
and inactivate JAK tyrosine kinases, SOCS-1 was recently de-
scribed to directly interact with the p65 subunit of NF-jB and
enhance its ubiquitinylation and degradation [27]. In HaCaT
cells, IL-4 induces SOCS-1 production [11]; it is tempting to
speculate that IL-4 would inhibit IL-8 promoter activation
through SOCS-1 expression leading to NF-jB proteolysis.
However, our data show that SOCS-1 overexpression alone
does not inhibit TNFa-induced IL-8 promoter activity (Fig.
3A). Moreover, pretreatment of the cells with IL-4 would be
necessary before TNFa stimulation to allow SOCS-1 synthesis.
Of note, we did not observe any diﬀerence in the extent of inhi-
bition by IL-4 whether the cells were co-stimulated with the
two cytokines or pretreated 3 h with IL-4 before TNFa stimu-
lation (data not shown).
We further characterized the transcription factor STAT6 as
a major eﬀector involved in the inhibitory eﬀect of IL-4 on IL-
8 expression using either a dominant negative form of STAT6
or the STAT6 deﬁcient cell line HEK 293T. Manna et al. [28]
reported that IL-4 downregulates TNF receptor expression in
diﬀerent cell lines. This process requires a 24 h IL-4 pretreat-
ment of the cells whereas in our experiments, inhibitory eﬀect
is obtained following simultaneous addition of IL-4 and TNFa
which makes unlikely an eﬀect of IL-4 on the receptor expres-
sion. Moreover, neither IjB a degradation nor NF-jB translo-
cation to the nucleus are aﬀected by IL-4 stimulation (Fig. 5A).
Furthermore, analysis of truncated forms of the promoter indi-
cates that even though the STAT6 binding site (position
1850 bp) may be involved, IL-4 inhibitory eﬀect occurs within
the 173 bp region of the promoter (Fig. 2B). This region har-
bors only several transcription factor binding sites including
CCAAT/enhancer-binding protein (C/EBP), NF-jB, AP-1
and Oct-1. Several hypothesis may be drawn to explain the
mechanisms by which IL-4 regulates IL-8 promoter activity.
Recent work has shown that NF-jB dependent gene expres-
sion requires the function of transcriptional co-activators
including CBP, SRC-1. . . [29]. STAT6 has been reported to di-
rectly bind to CBP [30]; this interaction leads to inhibition of
NF-jB transcriptional activity on a pNF-jB reporter lucifer-
ase assay through a titration of CBP by STAT6 [23]. Interest-
ingly, the transactivation domain of STAT6 which is also a
protein/protein interaction domain is required for STAT6 to
interfere with NF-jB activity. Our results agree with this
hypothesis (Figs. 4A and 5B) and this mechanism may account
for part of the inhibition properties of IL-4 signalling on IL-8
promoter activity. Furthemore, data from Bennett et al. [22]
indicate that in the HUVEC endothelial cell line, IL-4 suppres-
sion of TNFa-stimulated E-selectin gene transcription is med-
iated by STAT6 antagonism of NF-jB as a result of
overlapping binding sites for NF-jB and STAT6. The NF-
jB binding region of the IL-8 promoter (GTGGAA-
TTTCCTCTGAC) overlaps with a sequence closely related
to STAT6 consensus binding element (SBE) (TTCNNN-
NGAA). Such a sequence is able to bind STAT6 in an EMSA
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tion of NF-jB dependent IL-8 promoter activity by STAT6
could occur through competition between these two transcrip-
tion factors [22].
Although IL-8 transcription is mainly regulated by NF-jB,
other transcription factors participate in its regulation, acting
both positively or negatively. For example, while AP-1 is
known to stimulate IL-8 transcription, Oct-1 has a repression
eﬀect [14,31]. However, our experiments did not show any IL-4
interference with TNFa-induced AP-1 activation (data not
shown). In contrast, contradictory data are reported about
C/EBPb whose DNA binding site is located right upstream
the NF-jB site. C/EBPb was demonstrated to physically inter-
act with NF-jB and to cooperate or interfere with NF-jB
dependent IL-8 gene expression [32,33]. Indeed, Mikita et al.
[34] showed that the dissociation rate of STAT6 from its cog-
nate DNA element is slowed when C/EBPb binds at the neigh-
bouring site. Such conﬁguration is found in the IL-8 promoter
whereby C/EBPb and a potential STAT6 binding element are
closed to each other and this interaction could interfere with
NF-jB-dependent IL-8 promoter activation. Whether this po-
tential SBE and/or C/EBPb factor are involved remains to be
established.
In conclusion, in this study, we demonstrated that in kerat-
inocytes IL-4 inhibits TNFa-induced IL-8 expression at the
transcriptional level through activation of JAK and STAT6
pathway. We also showed that part of the downregulation ef-
fect occurs through inhibition of NF-jB transcriptional activ-
ity. Further analyses are needed to precisely identify the
promoter element(s) and transcription factor(s) involved in
this regulation.
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